Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Insulet Corporation (PODD : NSDQ)
 
 • Company Description   
Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.

Number of Employees: 2,300

 
 • Price / Volume Information   
Yesterday's Closing Price: $198.72 Daily Weekly Monthly
20 Day Moving Average: 605,143 shares
Shares Outstanding: 69.34 (millions)
Market Capitalization: $13,779.24 (millions)
Beta: 0.72
52 Week High: $323.62
52 Week Low: $181.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.14% -14.57%
12 Week -22.18% -14.46%
Year To Date -25.31% -10.57%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 NAGOG PARK
-
ACTON,MA 01720
USA
ph: 978-600-7000
fax: 978-600-0120
ir@insulet.com http://www.insulet.com
 
 • General Corporate Information   
Officers
Shacey Petrovic - Chief Executive Officer
Wayde McMillan - Chief Financial Officer
Lauren Budden - Chief Accounting Officer and Controller
Luciana Borio - Director
James R. Hollingshead - Director

Peer Information
Insulet Corporation (BJCT)
Insulet Corporation (CADMQ)
Insulet Corporation (APNO)
Insulet Corporation (UPDC)
Insulet Corporation (IMTIQ)
Insulet Corporation (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 45784P101
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 69.34
Most Recent Split Date: (:1)
Beta: 0.72
Market Capitalization: $13,779.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.31 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 151.90
Trailing 12 Months: 177.43
PEG Ratio: -
Price Ratios
Price/Book: 30.85
Price/Cash Flow: 184.70
Price / Sales: 12.07
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -4.76%
Sales Growth
vs. Year Ago Period: 17.08%
vs. Previous Quarter: -4.00%
ROE
03/31/22 - 15.81
12/31/21 - 9.47
09/30/21 - 0.63
ROA
03/31/22 - 3.85
12/31/21 - 2.54
09/30/21 - 0.18
Current Ratio
03/31/22 - 5.98
12/31/21 - 5.81
09/30/21 - 5.72
Quick Ratio
03/31/22 - 4.51
12/31/21 - 4.49
09/30/21 - 4.58
Operating Margin
03/31/22 - 6.78
12/31/21 - 4.52
09/30/21 - 0.32
Net Margin
03/31/22 - 3.91
12/31/21 - 1.53
09/30/21 - -2.84
Pre-Tax Margin
03/31/22 - 4.33
12/31/21 - 1.87
09/30/21 - -3.03
Book Value
03/31/22 - 6.44
12/31/21 - 8.07
09/30/21 - 7.22
Inventory Turnover
03/31/22 - 1.29
12/31/21 - 1.49
09/30/21 - 1.73
Debt-to-Equity
03/31/22 - 3.11
12/31/21 - 2.24
09/30/21 - 2.52
Debt-to-Capital
03/31/22 - 75.69
12/31/21 - 69.18
09/30/21 - 71.63
 

Powered by Zacks Investment Research ©